Who to call at Korsana Biosciences, and when

Fundz watches for the moments Korsana Biosciences starts buying, and tells you who to reach.

An alert the day Korsana Biosciences raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Korsana Biosciences, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Korsana Biosciences. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Cyclerion Announces Strategic Agreement with Medsteer for CYC-126 TRD Program.

Jan 05, 2026

Contract Type

agreement

WalthamBiotechnologyHealthcareHealth CareTherapeutics

Description

Cyclerion Therapeutics has formed a strategic agreement with Medsteer to enhance the development of its CYC-126 program for treatment-resistant depression. This collaboration aims to integrate Medsteer's innovative technology into Cyclerion's anesthesia-based approach, targeting specific brain states for improved patient outcomes.

Company Information

Company

Korsana Biosciences

Location

Waltham, Massachusetts, United States

About

Korsana Biosciences, Inc. is a biotechnology company focused on discovering and developing novel therapies for neurodegenerative diseases, particularly Alzheimer's disease. The company leverages its proprietary THETA™ therapeutic targeting platform to improve drug delivery and efficacy. Founded in 2024, Korsana aims to elevate patient care by creating potentially best-in-class therapeutics. The company's lead program, KRSA-028, targets amyloid beta and demonstrates strong preclinical data.